Piper Sandler analyst Edward Tenthoff lowered the firm’s price target on Point Biopharma (PNT) to $14 from $17 and keeps an Overweight rating on the shares following the agreement with Lantheus (LNTH). The analyst says the deal strengthens Point’s balance sheet. The company has a "dramatically strengthened" balance sheet with over $550M in cash to advance PNT2004 broadly in solid tumors, Tenthoff tells investors in a research note.
Published first on TheFly
Read More on PNT:
- Point Biopharma, Lantheus announce strategic collaboration for PNT2002, PNT2003
- Point Biopharma reports Q3 EPS (26c), consensus (28c)
- POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings
- Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003